CENP-V as a diagnostic marker for oocyte damage
Official title: CENP-V as a Potential Diagnostic Marker of Damage in Human Oocytes
Run by Vida Recoletas Sevilla · NCT06788379 · Data updated 2026-11-12
This study is testing if measuring a protein called CENP-V in human eggs can help identify damage from aging and freezing, which could improve fertility treatments for older women.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years to 45 Years |
| Sex | Women only |
| Enrollment | 160 (estimated) |
| Sponsor | Vida Recoletas Sevilla Academic / other |
| Locations | 1 site (Seville, SEVILLA) |
| Status | Recruiting |
| Started | October 4, 2024 |
| Main results expected | June 30, 2027 |
| Study ends | December 31, 2027 |
| Registry record updated | September 15, 2026 |
| Trial ID | NCT06788379 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates include women aged 36-45 with advanced maternal age or women aged 18-45 who have undergone oocyte vitrification.
✕Probably not a fit
Patients with conditions affecting oocyte quality, such as polycystic ovary syndrome or endometriosis, may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study aims to evaluate the levels of CENP-V protein in human oocytes to determine its potential as a diagnostic tool for assessing damage caused by aging and oocyte vitrification. The study will analyze discarded oocytes from women of advanced maternal age and control patients, both in their fresh state and after undergoing vitrification and thawing procedures. By focusing on the expression levels of CENP-V, the research seeks to understand its role in oocyte quality and the implications for fertility treatments.
Why it matters
Potential benefit: If successful, this study could provide a valuable diagnostic tool to assess oocyte quality and improve fertility outcomes for women undergoing assisted reproductive technologies.
How similar studies have gone: While the specific approach of using CENP-V as a diagnostic marker is novel, similar studies have explored protein markers in oocyte quality with varying degrees of success.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Group of patients with advanced maternal age (AMA): patients aged 36-45 years with AMA etiology as the main factor of infertility undergoing controlled ovarian stimulation. * Group of patients with vitrification / thawing of their oocytes: patients between 18-45 years of age who underwent oocyte vitrification to later, in the study cycle, thaw their oocytes. In this group we contemplate two subgroups: * Patients with vitrified / thawed oocytes and AMA: between 36-45 years at the moment of oocytes vitrification. * Patients with vitrified / thawed oocytes and non-AMA: between 18-35 years at the moment of oocytes vitrification. * Group of control patients: patients and donors with normal etiology, aged 18-35 years, undergoing controlled ovarian stimulation and collection procedures. Exclusion Criteria: * Patients with pathologies affecting the oocyte quality (PCO, POI, endometriosis, oncology patients, etc.). * Patients/donors with oocyte cryopreserved by slow freezing technique.
Where it's running
-
Vida Recoletas Sevilla S.L.
Seville, Sevilla, Spain Recruiting
Study contacts
- Study coordinator: Esther Santamaría López
- Email: esther.santamaria@gruporecoletas.com
- Phone: +34954286274
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Differential Granulosa Cell Transcriptome Profiling to Predict Ongoing Pregnancy
Aiming to see if differences in granulosa cell gene activity can predict ongoing pregnancy in IVF and oocyte donation with PGT-A.
-
Triggering ovulation at smaller versus larger follicle sizes in a modified natural cycle
This trial tests whether triggering ovulation when follicles are 13–16.9 mm works as well as triggering at 17–22 mm for people having a modified natural cycle frozen embryo transfer.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.